Current preclinical evidence supports continued investigation of CBD as a multi-target neuroprotective candidate in AD, provided that future studies use standardized, mechanism-focused and translationally relevant designs.
Sreenivasulu Sura, S. Jagadeesan, S. S. Masrudin et al.· Molecular Biology Reports· 0 citations
Alzheimer's Disease (AD) involves progressive brain changes at both the structural and ultrastructural levels, which begin long before patients present with clinical symptoms. These changes relate to the complex processes of amyloid-β deposition, tau accumulation, synaptic damage, glial activation, impaired vascular fu...
S. Sura, E. O. Okwuofu, Sowmya Ramakrishnappa et al.· Current Alzheimer Research· 0 citations
Findings support a model in which tau dysfunction results from the convergence of molecular aberrations and genetic susceptibility within a pathological network involving amyloid-β, neuroinflammation, and synaptic failure.
S. Sura, S. Jagadeesan, M. A. M. Moklas et al.· Molecular Biology Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.